Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 500 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 500 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 2000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 250 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 1000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 3000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b